Approval · Notice of Compliance 12848 · 2011
Q-SUMATRIPTAN: Notice of Compliance 12848
Issued December 6, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12848
- Date
- December 6, 2011
- Company
- Qd Pharmaceuticals UlcEtobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New Manufacturer and Product Name
- Therapeutic class
- 5-HT1 Receptor Agonist; Migraine Therapy
- Canadian reference product
- IMITREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| Q-SUMATRIPTAN | 02375184 | Cancelled Pre Market |
| Q-SUMATRIPTAN | 02375192 | Cancelled Pre Market |
| Q-SUMATRIPTAN | 02375206 | Cancelled Pre Market |
Medicinal ingredients
- SUMATRIPTAN 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 100 MG per TAB